ArticleScientific reports2026
Early fecal metabolomic profiling for predicting acute graft-versus-host disease following allogeneic hematopoietic stem cell transplantation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Acute graft-versus-host disease (GVHD) is a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Reliable early, noninvasive biomarkers for GVHD prediction remain limited. We conducted targeted fecal metabolomic profiling using liquid chromatography-tandem mass spectrometry in 77 allo-HSCT recipients at two time points: before conditioning (S1) and immediately after conditioning but prior to donor T-cell engraftment (S2). We assessed changes in metabolite profiles and their association with subsequent GVHD development. A multivariate logistic regression model and receiver-operating characteristic analysis were used to evaluate predictive performance. Conditioning induced significant alterations in neurotransmitters, bile acids, purine metabolism, tryptophan pathways, and phospholipase A2 (PLA2) activity. Post-conditioning, patients who developed GVHD showed elevated xanthine synthesis, reduced indoleamine 2,3-dioxygenase activity, and increased PLA2 metabolites. Reflecting the metabolic balance between anti-inflammatory omega-3 and pro-inflammatory omega-6 fatty acids, the eicosapentaenoic acid to arachidonic acid and docosahexaenoic acid to arachidonic acid ratios were consistently higher in the GVHD group. A five-metabolite-ratio panel demonstrated moderate discriminatory ability (area under the curve: 0.752, 95% confidence interval: 0.584-0.909). Early fecal metabolomic profiling after conditioning may capture metabolic patterns associated with later GVHD risk. This noninvasive approach shows potential to aid early risk stratification and improve preventative strategies in allo-HSCT patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.